23676/34351US=65 / Biol/Mol
Stoppelli MP, Andersen LM, Votta G, Andreasen PA. Engineered antagonists of uPA and PAI-1. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 721-58. ISBN 978-0-387-69056-8.

UPA; PAI-1; ATIVACAO DO PLASMINOGENIO; DISSEMINACAO DO CANCER; PROPRIEDADES BIOQUIMICAS; ADESAO CELULAR; MIGRACAO CELULAR; INVASAO CELULAR; PROLIFERACAO CELULAR; SOBREVIVENCIA; APOPTOSE; ATIVIDADE ENZIMATICA

23677/34351US=65 / Biol/Mol
Fingleton B. MMP inhibitor clinical trials-the past, present, and future. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 759-85. ISBN 978-0-387-69056-8.

INIBIDOR DE MMPS; ENSAIOS CLINICOS

23678/34351US=65 / Biol/Mol
Nagase H, Murphy G. Tailoring TIMPs for selective metalloproteinase inhibition. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 787-810. ISBN 978-0-387-69056-8.

TIMPS; INIBICAO SELETIVA DE METALOPROTEINASE; PROPRIEDADES BIOQUIMICAS

23679/34351US=65 / Biol/Mol
Yiotakis A, Dive V. Third-Generation MMP inhibitors: recent advances in the development of highly selective inhibitors. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 811-25. ISBN 978-0-387-69056-8.

INIBIDORES DE MMP; GRUPOS DE LIGACAO DE ZINCO; FOSFINICOS; TRANSICAO ANALOGOS

23680/34351US=65 / Biol/Mol
Fields GB. Protease-activated delivery and imaging systems. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 827-51. ISBN 978-0-387-69056-8.

PROTEASE; SISTEMAS DE IMAGEM; PRO-DROGAS; SISTEMA DE ENTREGA

23681/34351US=65 / Biol/Mol
Gill JH, Loadman PM. Development of tumour-selective and endoprotease-activated anticancer therapeutics. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 853-76. ISBN 978-0-387-69056-8.

DESENVOLVIMENTO DE TUMORES SELETIVOS; ENDOPROTEASE ATIVADO; TERAPEUTICA ANTICANCER

23682/34351US=65 / Biol/Mol
Ala-aho R, Baker AH, Kähäri VM. Targeting degradome genes via engineered viral vectors. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 877-94. ISBN 978-0-387-69056-8.

SEGMENTACAO GENES DEGRADOME; VETORES VIRAIS; VETORES RETROVIRAIS; VETORES DE ADENOVIRUS; VETORES DE VIRUS ADENO-ASSOCIADOS; BACULOVIRUS; HERPES SIMPLEX

23683/34351US=67 / Biol/Mol
Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2

23684/34351US=67 / Biol/Mol
Easton JB, Houghton PJ. mTOR: properties and therapeutics. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 33-53. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

MTOR; PROPRIEDADES; TERAPEUTICA; INIBIDORES; RAPAMICINA; CANCER; ENSAIOS CLINICOS

23685/34351US=67 / Biol/Mol
Sparano JA. Ras/Raf/MEK inhibitors. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 55-73. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

INIBIDORES; RAS; RAF; MEK

23686/34351US=67 / Biol/Mol
Neckers L, Ivy P. 17-AAG: targeting the molecular chaperone heat shock protein 90. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 75-95. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

17-AAG; CHAPERONE; PROTEINA DE CHOQUE TERMICO 90; CANCER; CHAPERONE MOLECULAR; TERAPIA ALVO; PLASTICIDADE GENETICA; ONCOGENE; GELDANAMICINA; ANSAMICINA BENZOQUINONA

23687/34351US=67 / Biol/Mol
Thiagalingam S, Faller DV. The cancer epigenome: cann it be targeted for therapy?. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 97-113. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER; EPIGENOMA; METILACAO DO DNA; DNA METIL TRANSFERASE; HISTONA ACETILTRANSFERASE; HISTONA-DESACETILASE; CODIGO DE HISTONAS; CODIGO EPIGENOMICO ATIVA; CODIGO EPIGENOMICO SILENCIADO; INIBIDOR DE HISTONA-DESACETILASE; TERAPIA DO CANCER

23688/34351US=67 / Biol/Mol
Wadler S. Molecular targeting in upper gastrointestinal malignancies. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 117-31. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

NEOPLASIAS GASTROINTESTINAIS SUPERIORES; SEGMENTACAO MOLECULAR; CARCINOMA HEPATOCELULAR; CANCER DE PANCREAS; CANCER DE ESTOMAGO; TERAPIA-ALVO

23689/34351US=67 / Biol/Mol
Sundermeyer ML, Bellacosa A, Meropol NJ. Molecular targeting of colorectal cancer: an idea whose time has come. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 117-31. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER COLORRETAL; SEGMENTACAO MOLECULAR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR

23690/34351US=67 / Biol/Mol
Schwartz JD, Llovet JM. Molecular targeting in hepatocellular carcinoma. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 165-210. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CARCINOMA HEPATOCELULAR; ALVO MOLECULAR; TERAPEUTICA ANTI-ANGIOGENESE; FATORES DE CRESCIMENTO

23691/34351US=67 / Biol/Mol
Goel A, Kozuch P. Molecularly targeted therapy in pancreatic cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 211-26. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PANCREAS; TERAPIA ALVO MOLECULAR; BEVACIZUMABE; CETUXIMABE; ERLOTINIBE; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); TERAPIA ANTI-ANGIOGENICA

23692/34351US=67 / Biol/Mol
Ho C, Davies AM, Lara PN, Gautschi O, Mach PC, Gumerlock PH, Gandara DR. Untargeted use of targeted therapy: a dilemma in non-small cell lung cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 227-40. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PULMAO DE CELULAS NAO-PEQUENAS; TERAPIA-ALVO; EGFR; VEGF; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL

23693/34351US=67 / Biol/Mol
Hahn O, Stadler W. Renal cell carcinoma: renal cell cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 241-61. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CARCINOMA DE CELULAS RENAIS; CANCER DE CELULAS RENAIS; TERAPIA MOLECULAR

23694/34351US=67 / Biol/Mol
Heath EI, Carducci MA. Targeted therapies for prostate cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 263-90. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PROSTATA; TERAPIA-ALVO; INIBIDORES DA VIA DE SINALIZACAO; INIBIDORES DA ANGIOGENESE; IMUNOTERAPIA; AGENTES ANTI-TUBULINA; AGENTES ANTI-MITOTICOS; AGENTES DE SEGMENTACAO ANTI-VASCULARES

23695/34351US=67 / Biol/Mol
Azad NS, Sarosy G, Kohn EC. Molecular targets in ovarian cancer and endometrial cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 291-308. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE OVARIO; CANCER ENDOMETRIAL; ALVOS MOLECULARES; TIROSINA-QUINASES; EGFR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); ONCOGENE; GENES SUPRESSORES DE TUMOR

Primeira | Anterior | Próxima | Última